Navigation Links
Cantel Medical Corp.'s Medivators Group Gains FDA 510(k) Approval For Its Advantage(TM) Plus Endoscope Reprocessing System
Date:2/27/2009

LITTLE FALLS, N.J., Feb. 27 /PRNewswire-FirstCall/ -- CANTEL MEDICAL CORP. (NYSE: CMN) announced today that the FDA has cleared its Medivators Advantage Plus Endoscope Reprocessing System and new Rapicide(R) PA High Level Disinfectant for sale in the United States. The Advantage Plus System, with its accompanying new chemistry, represents the latest in a long line of "state of the art", innovative reprocessing technologies that Medivators has been delivering to hospitals and stand-alone GI centers for over 20 years.

Andrew Krakauer, Cantel Medical's President stated, "We are very pleased to have broadened our regulatory approvals and can now sell the full Advantage Series in the United States. The Advantage Plus, together with its environmentally friendly Rapicide PA chemistry, brings a new, fully integrated and compliant dimension to busy endoscopy centers and is now available worldwide. We believe that this system should rapidly become the new standard of excellence for safety and efficacy, as well as user friendly operation."

Cantel Medical Corp. is a leading provider of infection prevention and control products in the healthcare market. Our products include specialized medical device reprocessing systems for renal dialysis and endoscopy, dialysate concentrates and other dialysis supplies, disposable infection control products primarily for the dental industry, water purification equipment, sterilants, disinfectants and cleaners, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. We also provide technical maintenance for our products and offer compliance training services for the transport of infectious and biological specimens.

For further information, visit the Cantel website at www.cantelmedical.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.


'/>"/>
SOURCE Cantel Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cantel Medical Corp. to Present at the 11th Annual Needham Growth Stock Conference
2. Cantel Medical Reports 72% Increase in Net Income on Record Sales - EPS of $0.20 vs. $0.12 for Quarter Ended October 31, 2008
3. Cantel Medical Corp. to Hold Conference Call to Discuss Results for Its First Quarter Ended October 31, 2008
4. Cantel Medical Corp. to Present at the Oppenheimer & Co. 19th Annual Healthcare Conference
5. Cantel Medical to Relocate Dutch Manufacturing Operations to the United States to Achieve Operating Savings
6. Cantel Medical Corp. and National Safety Council Launch Joint Initiative to Prepare Businesses and Individuals for Flu Pandemic
7. Healthcare Tech and the World: A Discussion About the Impact of Medical Automation on Healthcare
8. Kim Kardashian and Tia Carrere Celebrate Premiere of Revolutionary CellCeuticals(R) Biomedical Skin Treatments at Social Hollywood with Founders Dr. Garth Fisher and Paul Scott Premo
9. Fainting Most Common Medical Crisis on Planes
10. Winner Medical Receives European Patent Office Approval for PurCotton(TM) Production Method
11. University of Pittsburgh Medical Center to Manage New Health Center in Cyprus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, located ... training and leads programs. , In February, 2017, Empower Brokerage introduced their new ... Partners is designed to teach how to maximize their sales efforts, as well ...
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: ... events will interrelate. “End Time GPS” is the creation of published author, Wesley ... while working on military munitions and space-vehicle projects. Now, at age ninety-one, he shares ...
(Date:3/24/2017)... ... ... Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about a ... God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is the ... writing, especially about truth and human behavior. , Published by Christian Faith Publishing, Patti ...
(Date:3/23/2017)... Texas (PRWEB) , ... March 23, 2017 , ... The ... 3rd location in the greater Houston Area. The new location is located at 2255 ... Luke’s Hospital in Springwoods Village. This newest location will provide patients living in the ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Center at 10 North Broadway Avenue, will be an educational and exciting program ... instruction in the management of chronic pain. , Oklahoma is in a healthcare ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets ... the U.S.: Consumer Strategies" report to their offering. ... Pain ... approach and treat their physical pain, emphasizing consumer survey analysis, ... pain sufferers and adults who have selected illnesses/conditions strongly associated ...
(Date:3/24/2017)... , March 24, 2017 ShangPharma, ... high-quality and cost-effective drug development and discovery ... and biotechnology industry, announced today the intent ... ShangPharma will be consolidating the Contract Research ... under Shanghai ChemPartner. These entities include ChemPartner ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a ... Merck & Co., Inc., Biogen and Sanofi are involved in the development ... of which one is in Phase III stage, 15 are in Phase ...
Breaking Medicine Technology: